Critically ill infants are treated with dexamethasone (Dx) and other glucocorticoids to reduce inflammation and to promote lung and cardiac function. The neonatal immune system is immature, so neonatal dendritic cells (DCs) might be especially sensitive to glucocorticoid-mediated immunosuppression. To test this, we compared Dx treatment of monocyte-derived DCs from cord (CB) and adult blood (AB). Dx decreased CD1a levels on both AB and CB DCs. CB-treated cells also exhibited decreased expression of CD83 and increased expression of CD14, alterations not observed in AB DCs. Characteristic immature endocytic activity was sustained and enhanced in Dx-treated CB DCs, whereas AB DCs matured normally. Maintenance of endocytosis corresponded with CD14 expression. Dx markedly increased CB DC IL-10, a T cell helper 2 (Th2)-preferential cytokine, while reducing IL-12, a counterbalancing Th1 cytokine. AB DCs were also affected, but increases in IL-10 and decreases in IL-12 were more modest. Dx treatment also inhibited DC-induced T cell proliferation, but CB DCs were inhibited more. In short, neonatal DCs seemed to be especially sensitive to the immunosuppressive effects of Dx as indicated by altered phenotype, endocytic function, ability to stimulate T cells, and cytokine shift favoring Th2. These alterations in DC function are consistent with an increased risk for certain infections and atopic diseases. Cytokines that are produced by the placenta dampen allograft rejection and are thought to enhance the intrauterine survival of the fetus (1). This immune attenuation tends to direct an immune response toward T helper (Th) 2 and to weaken development of Th1-mediated immunity in newborns (2). The full range of adaptive immunity is gradually acquired through exposure to antigens that induce Th1 T cell responses and the development of a balanced immune system. When mothers go into premature labor, glucocorticoids, such as dexamethasone (Dx), are widely prescribed to enhance fetal lung maturation (3). In addition, glucocorticoids are used postnatally to reduce lung inflammation and to improve cardiovascular status in critically ill infants (4). Dx-treated infants have alterations in immune responsiveness as indicated by significantly reduced antibody responses after immunization (5); increased infections (6); multiple short-term adverse complications such as intestinal perforation (7-9), hypertension, and hypertrophic cardiomyopathy (10,11); and long-term effect such as increased risk for airway hyperresponsiveness and decreased pulmonary function (12,13).
Cytokines that are produced by the placenta dampen allograft rejection and are thought to enhance the intrauterine survival of the fetus (1) . This immune attenuation tends to direct an immune response toward T helper (Th) 2 and to weaken development of Th1-mediated immunity in newborns (2) . The full range of adaptive immunity is gradually acquired through exposure to antigens that induce Th1 T cell responses and the development of a balanced immune system. When mothers go into premature labor, glucocorticoids, such as dexamethasone (Dx), are widely prescribed to enhance fetal lung maturation (3) . In addition, glucocorticoids are used postnatally to reduce lung inflammation and to improve cardiovascular status in critically ill infants (4) . Dx-treated infants have alterations in immune responsiveness as indicated by significantly reduced antibody responses after immunization (5) ; increased infections (6); multiple short-term adverse complications such as intestinal perforation (7) (8) (9) , hypertension, and hypertrophic cardiomyopathy (10, 11) ; and long-term effect such as increased risk for airway hyperresponsiveness and decreased pulmonary function (12, 13) .
Several in vitro studies that were designed to identify the stage of maturation of each immune cell lineage in normal newborns have revealed that neonate naïve T (14 -16) and B (17, 18) cells are as competent as their adult counterparts. However, neonatal dendritic cells (DCs) are functionally less competent (19) and less capable of secreting cytokines that are essential for development of Th1 responses and balanced immunity (20) . DCs are the only professional antigenpresenting cells that are capable of priming neonatal naïve T cells for productive immune responses (21) (22) (23) . This unique ability suggests that DCs play a vital role in the establishment of adaptive immunity in neonates. Little is known about the developmental biology of neonatal DCs. Moreover, studies on the effect of glucocorticoids such as Dx on neonatal DCs have not been done.
Studies in the murine system show that glucocorticoids inhibit DC maturation (24) and decrease DC function by reducing the expression of adhesion molecules CD11a, CD43, CD54, and CD90 and co-stimulatory molecules CD80 and CD86. DCs that express this immature phenotype have diminished ability to prime Th cells and to enhance the formation of T regulatory cells (25) (26) (27) . Studies using human DCs derived from adult peripheral blood (AB) indicate that glucocorticoids 1) retard DC differentiation and maturation (28, 29) in a doseand length-of-exposure-dependent manner (30 -32); 2) decrease expression of co-stimulatory molecules (29, 32) ; 3) alter DC functioning by increasing endocytosis, increasing secretion of IL-10 (28,29,33,34) while decreasing IL-12 (29) ; and 4) weaken the immunostimulatory capacity of DCs in antigen presentation to autologous T cells in mixed lymphocyte reactions (29, 30, 35, 36) .
The murine and adult blood studies described above and the immaturity of the neonatal immune system prompted us to reason that neonatal DCs might be particularly sensitive to the immunosuppressive effects of glucocorticoids. To begin testing this hypothesis, we compared the effects of Dx on monocytederived DCs from neonatal cord blood (CB) and AB. We found that Dx inhibited the expression of DC phenotypic markers and modulated differentiation of DCs from CB but did not affect DCs from AB to the same extent. Dx also altered cytokine production, causing a surge of IL-10 secretion and a simultaneous decline of IL-12 secretion, thus dramatically altering the ratio of IL-10 to IL-12. Remarkably, Dx seemed to induce CB monocytes to retain their lineage and differentiate toward macrophage-like cells with increased endocytic ability and reduced ability to stimulate T cells. In short, the data suggest that the treatment of neonates with Dx may alter DC function, leading to a reduction of T cell priming and a cytokine milieu biased toward Th2. This alteration in the neonatal immune system would be consistent with the increased risk for certain infections and the early manifestation of reactive airway diseases that may evolve into atopic diseases such as asthma (12, 13) .
METHODS
Cell culture and Dx treatment. After informed consent in accordance with institutional review board standards, CB was collected into a sterile collection bag and processed within 24 h. Mononuclear cells were separated from red cells by sedimentation with a solution of hydroxyethyl starch followed by density centrifugation over Histopaque-1077 (Sigma Chemical Co., St. Louis, MO) to enrich the mononuclear cells. AB was collected by vena puncture, and buffy coat cells were separated. The cells that adhered after 1 h of incubation at 37°C (monocyte lineage cells) were cultured for 7 d in RPMI 1640 and 10% FCS enriched with 800 U/mL recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and 80 ng/mL recombinant human IL-4 (R & D, Minneapolis, MN). For maturing DCs, 20 ng/mL lipopolysaccharide (LPS; Sigma Chemical Co.) was added to the culture at day 5. Dx (Sigma Chemical Co.) at 10 Ϫ6 M was added to half of the cells during the differentiation phase, during the first 5 d of culture (Dx 0 -5 ), or during the last 2 d of culture (Dx 5-7 ). The concentration of 10 Ϫ6 M Dx was chosen on the basis of previous murine and adult peripheral blood in vitro studies (30, 37) , and our preliminary studies, in which we found that 10 Ϫ5 M was lethal, whereas 10 Ϫ8 and 10 Ϫ9 M had no effect on DC development. The culture media and reagents used were tested by the manufacturers, who indicate that their products are endotoxin-free.
Phenotypic marker analyses. Cells were incubated with the following mouse anti-human fluorescent MAb (Pharmingen, San Diego, CA) reactive with CD1a, CD83, CD86, CD14, or HLA-DP/Q/R (HLA-II) or with isotypematched antibodies as controls for 60 min at 4°C. Flow cytometry data were acquired using an Epics-XL-MCL flow cytometer (Coulter, Fullerton, CA). A subpopulation was defined for its high concentration of cells that express DC markers and analyzed for each marker percentage expression and mean fluorescence intensity (MFI) using WinMDI software.
Test of endocytic function via uptake of soluble protein.
The ability of cells to endocytose and catalyze the self-quenched green Bodipy dye conjugate of BSA (DQ-BSA; Molecular Probes, Eugene, OR), which involves clathrincoated pits, was used to measure endocytic function (38, 39) . Cells were incubated with DQ-BSA (10 g/mL in RPMI 1640 that contained 10% fetal bovine serum) for 1 h at 37°C, and controls were incubated on ice. The cells then were washed twice with PBS that contained 0.1% NaN 3 and 0.1% BSA (Sigma Chemical Co.) and incubated with phycoerythrin-labeled anti-CD14. Doubly labeled cells indicated endocytically active cells bearing the CD14 phenotype.
Cytokine determinations. Supernatant media from all cultures were collected after 5 d. Cells were resuspended in media with LPS (20 ng/mL) to stimulate IL-10 or IL-12 and incubated for 2 d more according to the protocol described above. Supernatants from the cultures with or without Dx were collected at the end of total 7 d and frozen at Ϫ80°C until assayed. Cytokine concentrations in the culture supernatants were assayed with commercial cytokine ELISA kits for human IL-10 and IL-12 according to the manufacturer's instructions (Amersham, Piscataway, NJ). The sensitivity of assays was Ͻ3 pg/mL for IL-10 and IL-12. All cytokine assays were carried out in duplicate.
T cell proliferation assays. T cells from CB or AB were prepared at the time of blood processing by separating CD3 ϩ cells from the nonadherent cells using CD3 cell enrichment magnetic beads (Miltenyi Biotec, Auburn, CA). Statistical analysis. All experiments in this study were conducted three or more times. Experiments were typically set up with three replicates, and when variability was a problem, power calculations were done to determine the number of replicates needed. The patterns within experiments were reproducible, although the magnitude of responses between experiments could be larger, which prompted us to illustrate some results using individual experiments rather than pool data from multiple experiments. Comparison of the mean of two groups of treatment (nontreated versus treated with Dx) was examined by two-tailed t test at a significance level of p Յ 0.05. All values were expressed as mean Ϯ SD unless otherwise stated.
RESULTS
Comparison of DC phenotypic marker expression by monocyte-derived DCs from AB and CB. After 5 d of culture with GM-CSF and IL-4, a subpopulation of both CB-and AB-derived monocytes expressed the dendritic cell differentiation markers CD1a and CD83 in similar percentages and MFI. A representative example is shown in Fig. 1 (compare A, row 1 versus 2 and the means from three to nine individual experiments summarized in Table 1 ). Note that these markers were expressed even more robustly by both CB and AB cells after addition of LPS during the last 2 d of culture to stimulate maturation (Fig. 1B , Table 1 ). The percentage expression of the functional markers CD86 and HLA-II in CB-and AB-derived cells was very similar (Fig. 1 , Table 1 ). The macrophage marker CD14 was higher at day 5 on CB than AB cells (12.6 126 versus 1.1%; p Ͻ 0.05; Table 1 ), but this difference disappeared after 2 d of culture with LPS (2.1 versus 1.6%).
Dx treatment inhibited DC phenotypic marker expression and promoted CD14 expression. After CB cells were cultured with Dx for 5 d (Dx 0 -5 ), a significant decrease in the expression of CD1a was apparent ( Fig. 2A, left) . , tended to down-regulate CD1a and CD83 expression, but, after LPS stimulation, only CD1a was significantly reduced (Fig. 2, right) . Expression of CD86 and HLA-II was not changed by Dx treatment of either CB or AB cells. The most dramatic Dx treatment effect was seen in the increased expression of the macrophage marker CD14 on CB-derived cells. After 5 d in Dx, the CB cells expressed 6-fold higher levels of CD14 than the untreated cells ( Fig. 2A, left) . The increased levels of CD14 persisted when the 5-d Dx treatment was followed by LPS stimulation and also were apparent when Dx was present only during LPS stimulation (Fig. 2B, left) . When Dx was given to AB cells during the differentiation stage, a tendency toward increased CD14 ϩ cells was apparent but did not reach statistical significance ( Fig. 2A, right) . When the AB cells were cultured for 2 d more with LPS and without Dx, CD14 expression decreased to control levels. There was no significant increase in AB-derived cell CD14 expression when Dx was added with LPS only during the maturation phase (Fig.  2B, right) .
Dx enhanced endocytosis in CB-derived cells. The ability of DCs to take up and catalyze the self-quenched green Bodipy dye conjugates of BSA was assessed with flow cytometry and used as a measure of endocytic activity. Control CB DCs and AB DCs exhibited the expected high level of endocytic activity after 5 d of differentiation (Fig. 3A, D stage, white bar) and the expected decrease in endocytic activity after LPS induced maturation (Fig. 3A, M stage, white bar) (41) . The addition of Dx to CB cells during the differentiation stage did not immediately affect the percentage of endocytosing cells (Fig. 3A , left, D stage, black bar), but, during the next 2 d of LPS stimulation without Dx, treated cells failed to exhibit the expected decrease in endocytic activity seen in the untreated cells (Fig. 3A, left, M stage, black bar) . When Dx was added to CB cells only during the maturation stage, they also maintained significantly more endocytosing cells (Fig. 3A, left, M (Fig. 3B, D stage, white bar, CB and AB). However, after LPS stimulation of the Dx 0 -5 -treated CB cells, there was the unexpected increase in the percentage of endocytosing cells described above (Fig. 3A , CB, M stage, black bar), and there also was a remarkable increase in the amount of BSA that each cell was able to take up (Fig. 3B, CB, M stage) . This phenomenon was not found in AB cells (Fig. 3, AB) . CD14 ؉ cells take up BSA. Because Dx-treated CB cells exhibited both increased CD14 expression and BSA uptake, we next determined whether the CD14 ϩ cells were responsible for the increased BSA uptake by examining the expression of CD14 of cells that contained high levels of BSA. CB cells that were treated with Dx 0 -5 showed increases of CD14 ϩ cells, and these same cells endocytosed BSA. This was apparent both at the end of the differentiation stage, D, and at the end of the maturation stage, M (Fig. 4, CB, black bar) . This Dx effect on CB cells was not seen when Dx was added only during the maturation stage (Dx [5] [6] [7] ; Fig. 4 , CB, hatched bar). Treated adult blood cells exhibited the same pattern of uptake by CD14 ϩ cells as cord blood cells, but the results were less dramatic (Fig. 4, AB) . -treated CB cells secreted significantly higher amounts of IL-10 and lower amounts of IL-12, so the ratio of IL-10 to IL-12 changed from 6:1 to 6219:1 (Fig. 5 left, black bars) . In contrast, Dx treatment during the last 2 d (Fig. 5 left, hatched bars) Fig. 5 right, hatched bars) also increased slightly (from 5:1 to 18:1). Thus, although the cytokine secretions for both CB and AB cells changed as a result of Dx treatment, the ratio of changes during differentiation were much greater for CB cells than for AB cells. In the absence of LPS during maturation, neither IL-10 nor IL-12 was detected at the end of the 7-d incubation period, indicating that cytokine secretion was LPS dependent (data not shown).
Comparison of the inhibitory effect of Dx on the ability of AB and CB DCs to induce auto-and allo-T cell proliferations. DCs have a remarkable ability to stimulate auto-and allo-MLRs. On average, CB DCs had~30 -50% of the ability of adult-derived DCs to stimulate auto-and allo-MLRs. Dx treatment further diminished their ability to stimulate autologous MLR (50%) and allo-MLR (~30%; Fig. 6A ). Similarly, Dx inhibited auto-and allo-MLRs of AB DCs, but the inhibition was less consistent and not as dramatic (Fig. 6B) .
DISCUSSION
Despite their known immunosuppressive activities, glucocorticoids, particularly Dx, are widely prescribed in the perinatal period to enhance fetal lung maturation (42), reduce lung inflammation (3), and improve cardiovascular function (4). Glucocorticoids have been shown to inhibit maturation of murine DCs (24) by reducing the expression of adhesion molecules and co-stimulatory molecules, resulting in diminished priming and activation of specific T cells (25, 26) or up-regulation of IL-10 secreting T regulatory cells (27) . Cultured adult human cells that are treated with glucocorticoids decrease expression of DC co-stimulatory molecules (29, 32) , retard DC differentiation and maturation (29 -32) , alter DC endocytic function, and weaken DC immunostimulatory capacity in antigen presentation to autologous T cells (29, 30, 33, 35, 36) . Our study confirmed most of these effects on AB DCs but, more important, showed a greater impact of Dx on monocyte-derived DCs from neonatal than adult blood cells. Nevertheless, it should be appreciated that cell-to-cell contact and mediators in the tissue milieu might influence the effect of Dx on DCs in vivo. 
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The phenotype of CB-DCs was very similar to that of AB DCs (Fig. 1, Table 1 ). One noticeable difference was that CB-derived cells expressed more CD14 than AB-derived cells after 5 d of culture, indicating the presence of more macrophage-like cells. However, both CB-and AB-derived cells expressed negligible CD14 after LPS stimulation for 2 d. Clearly, the adherent monocytes of both CB and AB have similar differentiation and maturation potentials.
Dx treatment decreased expression of the DC differentiation markers CD1a and CD83 of CB-derived cells even when treated just during the maturation stage. This result suggests that Dx may be able to alter DC maturation in a neonate even after normal differentiation. In contrast, AB DCs were resistant to Dx effects during the maturation stage. The expression of CD86 and HLA on DCs was not changed by Dx treatment of CB or AB cells, suggesting that these markers that are crucial for antigen presentation are more resistant to Dx-mediated suppression.
In contrast to the Dx-mediated depression of DC CD1a and CD83, the expression of the macrophage marker CD14 in cells derived from CB was increased relative to the untreated control both when Dx was added during the differentiation stage and when it was added only during the maturation stage. The results suggest that Dx is instrumental in sustaining macrophage-like cells in CB cultures, and these data are consistent with the hypothesis that Dx is a genomic-affecting steroid (43). Canning et al. (44) reported a similar increase of CD14 expression when Dx was added during the differentiation stage in a human adult monocyte/DC culture, although Dx effect during the maturation stage was not studied.
Mellman et al. (45) found that most newly differentiated DCs from AB take up large quantities of Ag, but this high level of endocytic ability decreases as LPS stimulates DCs to switch from Ag uptake to Ag processing during maturation. We also found this decreased DC endocytosis after maturation in both untreated AB-and CB-derived cells (Fig. 3A) . In contrast, Dx treatment maintained the high percentage of CB cells that were capable of taking up Ag during maturation, whether Dx was present during the differentiation or maturation stages. When given during the differentiation stage, Dx not only increased the percentage of CB cells that can take up Ag but also dramatically increased the amount of Ag that each cell takes up during stimulation with LPS (Fig. 3B, left) . Dx treatment during differentiation seems to be causing LPS-stimulated cells to maintain endocytic activity, rather than allowing normal DC maturation development from Ag uptake to Ag processing and presentation. This increase of cells that are capable of taking up Ag as a result of Dx treatment that was seen with CB cells was not seen with AB cells (Fig. 3) , suggesting, again, that CB cells are more susceptible to Dx treatment, especially during the differentiation stage of DC development.
The persisting CD14 ϩ cells after Dx treatment were responsible for two thirds of the increase observed in Ag uptake at the end of the differentiation stage, D, and almost all of the increase resulting by the end of the maturation stage, M (Fig.  4, CB) . AB cells also responded to Dx treatment during differentiation with modestly increased endocytic CD14 ϩ cells, concurring with the reported finding by Canning et al. (44) ; however, this increase was not retained during the maturation stage, M (Fig. 4, AB) . In addition, the percentage of endocytic CD14 ϩ CB cells was three times that of AB cells, reinforcing the notion that CB cells are more susceptible to Dx than AB cells.
After 7 d of culture in the absence of Dx, the levels of IL-10 and IL-12 produced by CB cells were comparable to those produced by AB cells (Fig. 5) . In contrast, others have reported weak IL-12 secretion by CB compared with AB mononuclear cells (46 -49) , suggesting that the ability of CB DCs to secrete IL-12 may not be as good as AB DCs. The reasons for these differences are not understood but may relate to differences in the state of the DCs in the different cultures.
The observation that Dx-treated adult human monocytederived DCs showed up-regulation of IL-10, a Th2-preferential cytokine with comparable down-regulation of IL-12 secretion, 
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DEXAMETHASONE AND NEONATAL DENDRITIC CELLS a counterbalancing Th1 cytokine, confirms the work of others (29, 33, 34, 44) . The observation that Dx added to CB cells during the differentiation stage dramatically amplified the modulation compared with AB cells extends previous observations (Fig. 5) . This large-scale alteration in the IL-10 to IL-12 ratio would greatly favor induction of Th2 T cells. It has been reported that a reduced amount of IL-12 production during the perinatal period can be linked to a predominantly Th2 atopic manifestation in later life (49) . Children who are exposed to glucocorticoids seem to be at increased risk for airway hyperresponsiveness and decreased pulmonary function (12,13) with a tendency to develop asthma. Our findings that Dx treatment skews toward a Th2 cell milieu would be consistent with this observation and contribute to the concern that treatment of children who have asthma with steroids may further bias them toward Th2 immunity and ultimately predispose these children toward more atopic disease.
Both AB and CB DCs could stimulate auto-and allo-MLRs (Fig. 6 ), although CB DCs were not as potent as AB DCs. Moreover, both AB and CB DCs were inhibited by Dx treatment, but the CB DCs were most affected. CB DCs were inhibited over all stimulator to T cell ratios studied, and inhibition was apparent during DC differentiation and maturation. The reduced ability of CB DCs to stimulate T cells when treated with Dx probably relates to a failure to differentiate as evidenced by the observed decrease in DC differentiation markers together with persistence of the monocyte marker CD14. Our data also showed an impressive surge of IL-10 secretion upon Dx treatment during the differentiation stage (Dx 0 -5 ; Fig. 5 ). Because IL-10 is a known inhibitor of DC maturation (50), Dx may be inhibiting the DC maturation process through this pathway, thus contributing to the reduced induction of T cell proliferation by Dx-treated DCs.
CONCLUSION
In conclusion, this study documents the suppressive effects of Dx on the development and function of DCs of neonatal origin. Dx retards the expression of essential DC phenotypic markers, increases the number of CD14 ϩ cells that are more efficient in endocytosis but less effective as antigen presenters, amplifies the secretion of Th2-biased IL-10, and decreases the induction of T cell proliferation. These findings suggest that treatment of neonates with Dx may adversely alter DC cell function, reduce naïve T cell priming, deter the development of active immunity, and increase the potential for opportunistic infections such as candidiasis (51) (52) (53) . Alteration of the IL-10 to IL-12 ratio that leads to a Th2 bias may hasten and perpetuate the manifestation of atopic diseases such as asthma. These clinical implications support a need for comparative studies with other glucocorticoids to determine whether glucocorticoids such as betamethasone, methylprednisolone, or prednisolone, which do not have the same gene-modifying effects as Dx (43), might provide the needed benefits to neonates without altering DC function. 
